IP Library Granted Patent US 7,507,584
Granted Patent B2
US 7,507,584 · App. 11/587,297 · Granted Mar 24, 2009

Method for the diagnosis of chronic stress and related disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,507,584
App. No.
11/587,297
Granted
Mar 24, 2009
Kind
B2
Abstract

Methods for diagnosing chronic stress in patients by first determining the level of one or more analytes in a patient sample and establishing the significance of the one or more analyte levels.

Claims (11)

1. A method of diagnosis of chronic stress in a patient, which comprises:

(a) determining the level of each of analytes vascular endothelial growth factor (VEGF), monocyte chemotactic protein-1 (MCP1) and epidermal growth factor (EGF) in a sample taken from the patient; and

(b) establishing the significance of each analyte level by comparing each analyte level to the same analyte levels measured in a healthy control sample, and diagnosing chronic stress in the patient when each analyte level is elevated relative to the analyte levels measured in the healthy control sample.

2. A method according to claim 1 , wherein the sample is a blood sample.

3. A method of diagnosis of chronic stress in a patient, which comprises:

(a) determining the level of each of analytes vascular endothelial growth factor (VEGF), monocyte chemotactic protein-1 (MCP1) and epidermal growth factor (EGF) in a sample taken from the patient; and

(b) establishing the significance of each analyte level by comparing each analyte level with those of a control sample, wherein the control sample is from a person who is not suffering from a major depressive disorder and diagnosing chronic stress in the patient when each analyte level is elevated relative to the analyte levels in the control sample.

4. A method according to claim 1 or 2 wherein step (a) additional comprises determining the level of interluken-8 (IL-8).

5. A method according to claim 4 wherein step (a) additional comprises determining the level of thyroid stimulating hormone (TSH).

6. A method according to claim 1 or 2 wherein step (a) additional comprises determining the level of thyroid stimulating hormone (TSH).

7. A method according to claim 3 , wherein the patient sample is a blood sample.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVENYANCE PREVIOUSLY RECORDED AT REEL: 055950 FRAME: 0471. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 20, 2021
From: RANDOX LABORATORIES LIMITED
To: NORTHERN BANK LIMITED
Reel/Frame 056210/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2021
From: RANDOX LABORATORIES LIMITED
To: NORTHERN BANK LIMITED
Reel/Frame 055950/0471 →